Teriparatide is one of the relatively small number of peptide drugs that actually builds new bone rather than simply slowing its loss, and it has a two-decade FDA-approval history that makes it a useful case study in how a drug's safety label can evolve as real-world evidence accumulates.
What It Is
Teriparatide is a synthetic fragment (amino acids 1-34) of human parathyroid hormone, sold under the brand name Forteo and available in generic form. Unlike most osteoporosis medications, which work by slowing the breakdown of existing bone, teriparatide is an anabolic agent: given in small daily doses, it actually stimulates osteoblasts, the cells responsible for building new bone tissue, leading to measurable increases in bone density over time.
Regulatory Status
Teriparatide is FDA-approved for the treatment of osteoporosis in postmenopausal women and men at high risk of fracture, and for bone loss associated with sustained glucocorticoid (steroid) therapy. It was first approved in 2002 and is typically prescribed for a defined treatment course, since its bone-building effect has mainly been studied over a limited duration.
The Osteosarcoma Warning, and Why It Changed
When teriparatide was approved, it carried a boxed warning, the FDA's most serious label warning, about osteosarcoma (a rare bone cancer) risk, based on findings in rat studies where animals given very high, long-term doses developed bone tumors. That's an important example of the animal-to-human evidence gap this site discusses elsewhere: the rat studies used doses and durations well beyond typical human treatment, and rodent bone biology differs from human bone biology in ways that make this kind of finding hard to extrapolate directly.
To address the uncertainty, the FDA required a long-term postmarketing surveillance program tracking real-world osteosarcoma cases in patients treated with teriparatide. After many years of data collection covering tens of thousands of patients, that surveillance did not show an increased osteosarcoma risk in humans at approved doses, and regulators subsequently removed the boxed warning from the label, a rare example of a black-box warning being formally retired based on accumulated human safety data rather than added because of it.
What the Evidence Shows
Teriparatide's efficacy for increasing bone mineral density and reducing fracture risk in postmenopausal osteoporosis is supported by randomized, placebo-controlled human clinical trials, not just animal or observational data, which is a meaningfully stronger evidence base than many peptides discussed elsewhere on this site. Because the drug is generally used for a defined treatment window and its bone-building effect can wane afterward, patients are typically transitioned to a different class of osteoporosis medication once a teriparatide course ends, to help maintain the bone density gained.
Safety Considerations
Common side effects include nausea, leg cramps, and dizziness, and the drug is not recommended for patients with certain preexisting bone conditions or those already at elevated cancer risk, given its original mechanism-based caution. As with any prescription therapy, the decision to start, continue, or stop teriparatide should be made with a physician who can weigh personal fracture risk, treatment history, and duration limits.
The Bottom Line
Teriparatide is a genuinely FDA-approved, clinically studied peptide with real anabolic bone-building effects in humans, and its warning-label history is a useful, well-documented example of regulatory decisions being updated as evidence, not marketing, changes.